» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
 
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: Effects of nano curcumin supplementation on the reduction of inflammation and mortality in patients with coronavirus 2019 admitted to ICU ward of Tabriz Imam Reza Hospital Design: A randomized, controlled, double-blind, placebo-controlled clinical trial Settings and conduct: Imam Reza Hospital, This study is a double-blind randomized clinical trial on two statistical populations, including patients with coronavirus in the ICU who receive four drugs oseltamivir, hydroxychloroquine, lopinavir, and ribavirin. Now, patients with the above conditions are divided into two groups receiving 240 mg daily oral nano curcumin and placebo recipients, both of which will have a treatment duration of 14 days. After sampling from both groups and isolating mononuclear cells (PBMC) from them, the expression levels of IL-1, IL-6, IL-17, and TNF-α genes were quantified using the Quantitative Real-Time PCR method. And after the intervention, it will be measured. On the other hand, the ELISA technique is used to evaluate the levels of IL-1, IL-6, IL-17 and TNF-α secreting cytokines. Participants/Inclusion and exclusion criteria: • In accordance with clinical diagnosis or etiologic criteria for coronavirus pneumonia (COVID-19). • Willingness to cooperate • Age range from 18 to 8 years Not logged in: • Nutrition and antioxidant supplements and alpha-lipoic acid during one month before the study • Pregnancy and lactation • Severe immune suppression (HIV infection, long-term use of immunosuppressive agents) Intervention groups: The intervention group will receive 240 mg nano curcumin and the control group will receive placebo capsules daily. Patients will be given daily capsules in packs containing 60 capsules and we ask patients to take three capsules daily for 14 days. Main outcome variables: Gene expression rate; cytokine secretion rate; clinical observations; laboratory observations
IRCTID: IRCT20200324046851N1
  1. Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19
  2. Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD)
  3. The effect of Nanocurcumin on gene expression of proinflammantory factors in peripheral blood mononuclear cells and serum levels of endothelial function factors in hemodialysis patients
  4. The effect of curcumin supplementation on clinical Outcomes, and some Inflammatory Markers in Patients with Ulcerative Colitis
  5. The effect of Curcumin, Nigella Sativa, and Curcumin-Nigella Sativa on cellular- molecular and clinical outcomes related to primary osteoporosis among postmenopausal women: A triple blind randomized controlled trial
  6. Evaluation of anti-inflammatory effects of omega-3 in children with asthma based on clinical symptoms, spirometry and inflammatory and anti inflammatory cytokines in serum
  7. Comparing the effects of supplementation Krstyn, Vitamin C, endothelial function, oxidative stress, exercise performance, Indicators of inflammation and muscle damage in athletes
  8. The effect of Resveratrol supplement on metabolic profiles and genes expression of Sirtuin-1، TNF-α، TGF-β، IL-1، PPARγ in diabetetic coronary artery disease patients
  9. Evaluation of gene expression, methylation and secretory level of cytokines and inflammatory chemokines in COPD patients receiving nanocurcumin supplementation compared with patients receiving placebo
  10. The effect of curcumin supplementation on inflammatory factors and prognosis in septic ICU patients
Loading...